NorthRock Partners LLC Raises Position in Insulet Corporation $PODD

NorthRock Partners LLC grew its position in Insulet Corporation (NASDAQ:PODD) by 13.6% during the 2nd quarter, Holdings Channel reports. The fund owned 1,103 shares of the medical instruments supplier’s stock after buying an additional 132 shares during the quarter. NorthRock Partners LLC’s holdings in Insulet were worth $347,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after acquiring an additional 178,976 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Groupama Asset Managment boosted its holdings in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after acquiring an additional 3,759 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after acquiring an additional 27,408 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Insulet by 23.4% in the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after acquiring an additional 120,197 shares in the last quarter.

Insulet Stock Performance

Shares of PODD opened at $316.29 on Friday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $22.26 billion, a P/E ratio of 96.14, a PEG ratio of 2.61 and a beta of 1.40. The company has a 50-day moving average of $325.99 and a two-hundred day moving average of $301.60. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on PODD shares. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Wells Fargo & Company boosted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. The Goldman Sachs Group decreased their price objective on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Finally, Rothschild & Co Redburn boosted their price objective on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $348.05.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.